116 related articles for article (PubMed ID: 32316711)
1. [Genetic Profile of Young Chinese Patients with Lung Adenocarcinoma].
Liang Y; Hou H; Jiang M; Zhang C; Liu D; Zhang X
Zhongguo Fei Ai Za Zhi; 2020 Apr; 23(4):239-246. PubMed ID: 32316711
[TBL] [Abstract][Full Text] [Related]
2. Comprehensive Molecular Characterization of Young Chinese Patients with Lung Adenocarcinoma Identified a Distinctive Genetic Profile.
Hou H; Zhu H; Zhao H; Yan W; Wang Y; Jiang M; Liu B; Liu D; Zhou N; Zhang C; Li P; Chang L; Guan Y; Wang Z; Zhang X; Li Z; Fang B; Zhang X
Oncologist; 2018 Sep; 23(9):1008-1015. PubMed ID: 29700208
[TBL] [Abstract][Full Text] [Related]
3. Genomic Signature of Driver Genes Identified by Target Next-Generation Sequencing in Chinese Non-Small Cell Lung Cancer.
Wen S; Dai L; Wang L; Wang W; Wu D; Wang K; He Z; Wang A; Chen H; Zhang P; Dong X; Dong YA; Wang K; Yao M; Wang M
Oncologist; 2019 Nov; 24(11):e1070-e1081. PubMed ID: 30902917
[TBL] [Abstract][Full Text] [Related]
4. Unique prevalence of oncogenic genetic alterations in young patients with lung adenocarcinoma.
Tanaka K; Hida T; Oya Y; Yoshida T; Shimizu J; Mizuno T; Kuroda H; Sakakura N; Yoshimura K; Horio Y; Sakao Y; Yatabe Y
Cancer; 2017 May; 123(10):1731-1740. PubMed ID: 28177518
[TBL] [Abstract][Full Text] [Related]
5. Unique profiles of targetable genomic alterations and prognosis in young Chinese patients with lung adenocarcinoma.
Chen L; Hu X; Wu H; Liu J; Mu X; Wu H; Zhao Y
Pathol Res Pract; 2019 Jun; 215(6):152407. PubMed ID: 30962004
[TBL] [Abstract][Full Text] [Related]
6. Detection of Novel NRG1, EGFR, and MET Fusions in Lung Adenocarcinomas in the Chinese Population.
Pan Y; Zhang Y; Ye T; Zhao Y; Gao Z; Yuan H; Zheng D; Zheng S; Li H; Li Y; Jin Y; Sun Y; Chen H
J Thorac Oncol; 2019 Nov; 14(11):2003-2008. PubMed ID: 31382039
[TBL] [Abstract][Full Text] [Related]
7. Distinctive targetable genotypes of younger patients with lung adenocarcinoma: a cBioPortal for cancer genomics data base analysis.
Hou H; Zhang C; Qi X; Zhou L; Liu D; Lv H; Li T; Sun D; Zhang X
Cancer Biol Ther; 2020; 21(1):26-33. PubMed ID: 31594446
[TBL] [Abstract][Full Text] [Related]
8. Assessment of mutational profile of Japanese lung adenocarcinoma patients by multitarget assays: a prospective, single-institute study.
Serizawa M; Koh Y; Kenmotsu H; Isaka M; Murakami H; Akamatsu H; Mori K; Abe M; Hayashi I; Taira T; Maniwa T; Takahashi T; Endo M; Nakajima T; Ohde Y; Yamamoto N
Cancer; 2014 May; 120(10):1471-81. PubMed ID: 24700479
[TBL] [Abstract][Full Text] [Related]
9. Concomitant occurrence of EGFR (epidermal growth factor receptor) and KRAS (V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog) mutations in an ALK (anaplastic lymphoma kinase)-positive lung adenocarcinoma patient with acquired resistance to crizotinib: a case report.
Rossing HH; Grauslund M; Urbanska EM; Melchior LC; Rask CK; Costa JC; Skov BG; Sørensen JB; Santoni-Rugiu E
BMC Res Notes; 2013 Nov; 6():489. PubMed ID: 24279718
[TBL] [Abstract][Full Text] [Related]
10. Driver gene alterations in lung adenocarcinoma: Demographic features of 2544 Chinese cases.
Hu M; Zhang T; Yang Y; Che N; Li J; Liu Z; Li B
Int J Biol Markers; 2020 Dec; 35(4):44-50. PubMed ID: 33063618
[TBL] [Abstract][Full Text] [Related]
11. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma.
Han JY; Kim SH; Lee YS; Lee SY; Hwang JA; Kim JY; Yoon SJ; Lee GK
Lung Cancer; 2014 Aug; 85(2):161-7. PubMed ID: 24857785
[TBL] [Abstract][Full Text] [Related]
12. Mutation Profile of Resected
Zhao ZR; Lin YB; Ng CSH; Zhang R; Wu X; Ou Q; Chen W; Zhou WJ; Lin YB; Su XD; Shao YW; Long H
Oncologist; 2019 Oct; 24(10):1368-1374. PubMed ID: 30872465
[TBL] [Abstract][Full Text] [Related]
13. Benefit of Targeted DNA Sequencing in Advanced Non-Small-Cell Lung Cancer Patients Without EGFR and ALK Alterations on Conventional Tests.
Byeon S; Lee B; Park WY; Choi YL; Jung HA; Sun JM; Ahn JS; Ahn MJ; Park K; Lee SH
Clin Lung Cancer; 2020 May; 21(3):e182-e190. PubMed ID: 31839532
[TBL] [Abstract][Full Text] [Related]
14. Analysis of EGFR, EML4-ALK, KRAS, and c-MET mutations in Chinese lung adenocarcinoma patients.
Xia N; An J; Jiang QQ; Li M; Tan J; Hu CP
Exp Lung Res; 2013 Oct; 39(8):328-35. PubMed ID: 23919423
[TBL] [Abstract][Full Text] [Related]
15. Utility of incorporating next-generation sequencing (NGS) in an Asian non-small cell lung cancer (NSCLC) population: Incremental yield of actionable alterations and cost-effectiveness analysis.
Tan AC; Lai GGY; Tan GS; Poon SY; Doble B; Lim TH; Aung ZW; Takano A; Tan WL; Ang MK; Tan BS; Devanand A; Too CW; Gogna A; Ong BH; Koh TPT; Kanesvaran R; Ng QS; Jain A; Rajasekaran T; Lim AST; Lim WT; Toh CK; Tan EH; Lim TKH; Tan DSW
Lung Cancer; 2020 Jan; 139():207-215. PubMed ID: 31835042
[TBL] [Abstract][Full Text] [Related]
16. Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
Zhou X; Shou J; Sheng J; Xu C; Ren S; Cai X; Chu Q; Wang W; Zhen Q; Zhou Y; Li W; Pan H; Li H; Sun T; Cheng H; Wang H; Lou F; Rao C; Cao S; Pan H; Fang Y
Cancer Sci; 2019 Oct; 110(10):3382-3390. PubMed ID: 31444835
[TBL] [Abstract][Full Text] [Related]
17. Aberrant status and clinicopathologic characteristic associations of 11 target genes in 1,321 Chinese patients with lung adenocarcinoma.
Zhao M; Zhan C; Li M; Yang X; Yang X; Zhang Y; Lin M; Xia Y; Feng M; Wang Q
J Thorac Dis; 2018 Jan; 10(1):398-407. PubMed ID: 29600072
[TBL] [Abstract][Full Text] [Related]
18. Genomic alterations and clinical outcomes in patients with lung adenocarcinoma with transformation to small cell lung cancer after treatment with EGFR tyrosine kinase inhibitors: A multicenter retrospective study.
Wang W; Xu C; Chen H; Jia J; Wang L; Feng H; Wang H; Song Z; Yang N; Zhang Y
Lung Cancer; 2021 May; 155():20-27. PubMed ID: 33714778
[TBL] [Abstract][Full Text] [Related]
19. Mutation Profile Assessed by Next-Generation Sequencing (NGS) of Circulating Tumor DNA (ctDNA) in Chinese Lung Adenocarcinoma Patients: Analysis of Real-World Data.
Zhao S; Cong X; Liu Z
Biomed Res Int; 2021; 2021():8817898. PubMed ID: 33997043
[TBL] [Abstract][Full Text] [Related]
20. Dual-energy spectral CT characteristics in surgically resected lung adenocarcinoma: comparison between Kirsten rat sarcoma viral oncogene mutations and epidermal growth factor receptor mutations.
Li M; Zhang L; Tang W; Duan JC; Jin YJ; Qi LL; Wu N
Cancer Imaging; 2019 Nov; 19(1):77. PubMed ID: 31783917
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
